Novartis' myasthenia gravis asset iptacopan granted FDA Orphan Drug status
Source: SeekingAlpha
2025-12-19 14:57:28 ET
More on Novartis
- Novartis AG (NVS) Discusses Social Impact, Global Health Initiatives, and Sustainability Strategy Transcript
- Novartis AG (NVS) Discusses Social Impact, Global Health Initiatives, and Sustainability Strategy - Slideshow
- Novartis AG (NVS) Shareholder/Analyst Call Transcript
- More pharmas expected to sign drug pricing deals with Trump on Friday - report
- Novartis sees positive results when ianalumab added to Promacta for thrombocytopenia
Read the full article on Seeking Alpha
For further details see:
Novartis' myasthenia gravis asset iptacopan granted FDA Orphan Drug status
Novartis AG
NASDAQ: NVS
NVS Trading
-1.36% G/L:
$143.37 Last:
954,184 Volume:
$144.01 Open:
NVS Latest News
February 24, 2026 04:52:00 pm
Could Novartis Stock Quietly Help You Build a Millionaire Retirement Portfolio?
NVS Stock Data
$303,205,301,793
1,889,070,162
N/A
868
N/A
Pharmaceuticals
Healthcare
CH
Basel
